|Bid||133.60 x 200|
|Ask||133.75 x 100|
|Day's Range||132.24 - 142.47|
|52 Week Range||96.18 - 145.42|
|PE Ratio (TTM)||63.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Alexion Pharmaceuticals (ALXN) are rising today after the biotech company beat earnings forecasts and raised its guidance. Leerink analyst Geoffrey Porges and Bradley Canino call today's report "the most important" of the large-cap biotech stocks: This morning Alexion announced Q2 revenue of $912mm, which was a 7% beat against consensus of $849mm and an 8% beat vs. our estimate of $846mm (which implied sequentially lower revenue given management’s conservative commentary last quarter and the attrition of patients on Soliris to clinical trials). Shares of Alexion Pharmaceuticals have gained 2% to $133.72 at 12:18 p.m. today, but had been up as much as 8.6% earlier today.
On a per-share basis, the New Haven, Connecticut-based company said it had profit of 73 cents. Earnings, adjusted for one-time gains and costs, were $1.56 per share. The results beat Wall Street expectations. ...
Alexion Pharmaceuticals said Thursday that it’s scrapping a handful of drug development programs as part of a reorganization, including its partnership deals with a pair of Cambridge biotechs. Moderna : Alexion’s 2014 deal with Moderna, one of the state’s largest privately-held biotechs, covered treatments that use messenger RNA, or mRNA — molecules that recruit the body's own cells to create proteins to fight rare diseases. Under that agreement, Alexion paid Moderna $100 million upfront in exchange for the option to partner on up to 10 products.